Home > Cardiology > VICTORION-INCEPTION: inclisiran immediately after ACS for secondary prevention

VICTORION-INCEPTION: inclisiran immediately after ACS for secondary prevention

Presented By
Dr Jeffrey Anderson
AHA 2022

VICTORION-INCEPTION (NCT04873934) is a phase IIIb, randomised, parallel-group, open-label, multicentre, US-based trial currently enrolling patients at high risk for a recurrent cardiovascular (CV) event in the first year following acute coronary syndrome (ACS) to receive inclisiran to reduce low-density lipoprotein cholesterol (LDL-C) levels plus usual care or usual care. The rationale and design of this study was presented at this year’s American Heart Association’s Scientific Sessions  held 5-7 November, 2022, in Chicago, IL, by Dr Jeffrey Anderson [1].

Afbeelding met persoon, stropdas, kleding, dragen Automatisch gegenereerde beschrijving Many patients fail to achieve guideline recommended LDL-C <70 mg/dL within 12 months of an ACS event. Early LDL-C evaluation and intensification of lipid-lowering treatment after recent ACS may reduce recurrent CV event risk. In prior phase III trials, inclisiran plus maximally tolerated statin therapy effectively reduced LDL-C in patients with established ASCVD [2-5]. Because patients with an ACS within 3 months of screening were excluded from these trials, the efficacy of inclisiran in these patients is unknown.


Medicom spoke with Dr Anderson to learn more:

Medicom: Could you please place the data in the context of what the unmet need is?

“Sure. I just enrolled a patient in the study before this interview, so we’re going strong.  (PW: Congratulations). The gap in optimal therapy after a myocardial infarction (MI) is aggressively treating lipid levels. We know that lipid levels, LDL cholesterol particularly, is a major risk factor, probably the most potent risk factor for myocardial infarction along with hypertension, diabetes, and smoking, of course, all major modifiable risk factors. We have excellent therapies now for lowering LDL cholesterol, but we found that perhaps because of attention to other priorities after an MI, that often, optimal therapy is not provided by the time of discharge or early in the post-op/post-admission timeframe.

The rationale behind VICTORION-INCEPTION is to see whether we could augment early therapy to bring levels of LDL cholesterol down to at least a guideline-recommended levels within the first few weeks after an MI by potentially adding-on inclisiran to usual care. Inclisiran is a simple injection, which can dramatically augment lipid lowering by 50-60%, beyond what is accomplished by statins alone. The LDL cholesterol threshold for trial entry is 70 mg/dL, meaning that patients who already have lower levels of LDL cholesterol, would not be given inclisiran on top of their usual care. In fact, the new cholesterol consensus pathway guidelines for treating cholesterol from the American College of Cardiology suggest that after an acute MI the newly recommended threshold is even 55 mg/dL [6].

For this study, however, we are using the more traditional cut-off level of 70 mg/dL. That gives us ample room to improve the achieved LDL levels with additional therapy. If a consenting patient has an LDL level over 70 mg/dL at a screening visit, they could be randomised to either inclisiran or usual care alone- cardiologist’s choice- which might even include a PCSK9 inhibitor or even inclisiran, if that is what the cardiologist chooses. For example, this patient I had today was randomised to aggressive therapy with inclisiran. So, I gave him an injection of inclisiran to try to bring his level down from >100 mg/dL to certainly less than 70 mg/dL and potentially even less than 55 mg/dL. And then he will come back in that arm at 3 months to get a booster injection and then again 6 months later. Thereafter the participants will get additional injections every 6 months on treatment.

The primary endpoint in the VICTORION-INCEPTION study is the percentage of patients that achieve an LDL cholesterol less than 70 mg/dL at 1 year. Of course, we will also be looking at the overall response. In other words, the change from the baseline level on treatment in either arm will be our primary outcome measure. This trial is not as tightly controlled as in other studies; we have created maximum flexibility in the design for the treating cardiologist to do whatever needed to optimise LDL levels. In many respects, the control arm here is real-world evidence. In the investigational arm, those patients get inclisiran upfront in addition to anything else that is added on. We like to have the participants continue on their statin, of course. We think that the combination of statin and inclisiran is a really wonderfully complimentary regimen to reduce risk and optimise outcomes.

That’s the study in brief. The number of patients in the study is not very large, just a few hundred. However, we hope to be fully enrolled sometime early 2023, and then follow-up for another year with the results. We hope the topline data will be available in the first half of 2024, and so we look forward to that as a way to potentially optimise treatment after myocardial infarction, which is a very high-risk period of time for a recurrent event.”

Medicom: Could you comment on the secondary outcomes of the study?

“Yes, there are many secondary outcomes, looking at different levels and we obviously always look for clinical events, but this study is not large enough to have the power to determine the impact on events. That is being tested in another study that we’re involved with as well, called ORION-4, which is targeting 15,000 patients worldwide, and I think we’re beyond 10,000 at this point in terms of enrolment. This study will have the power to look at the ability to reduce heart attacks and strokes and cardiovascular deaths. We’ll certainly look at that and we’ll look at safety endpoints as well.

But that question is being tested in the ORION-4 study, which will not be reporting until 2026-2027.”

Medicom: Were there inclusion criteria besides LDL levels > 70 mg/dL?

“The patients were all hospitalised for an acute myocardial infarction or acute coronary syndrome, either after emergency room evaluation or in-hospital inpatient admission, but in some rare cases, outpatient management was allowed. The participant will have to be hospitalised or at least evaluated as an emergency situation and receive a definite diagnosis made of acute coronary syndrome. Beyond that, there could be either a STEMI, or a non-STEMI, or it could be a documented unstable angina. Those simple requirements qualify you to be screened for the study. Beyond that really there are not too many additional criteria except that after initial treatment and hospital discharge then we draw labs and the LDL cholesterol has to be over 70 mg/dL. The labs will also have to show a minimal renal function threshold, a GFR of >20.”

Medicom: What are some of the possible impacts you see this particular study bringing with it as opposed to the ORION-4?

“VICTORION-INCEPTION will provide shorter term data while we’re waiting for the ORION-4 to roll out, but they also ask somewhat different questions. With VICTORION-INCEPTION, we want to see: of those screened, how many are achieving LDLs less than 70 mg/dL? In other words, what is the gap in terms of optimal management of MI patients? That will be very important to determine. Assuming the data makes us recognise that these patients are suboptimally treated, that data will inform the treating cardiologist for the other aspects of the patient’s care.

Another distinction from the other ORION trials is the population; patients in all the other trials generally could not be enrolled until at least 3 months after a coronary event. We are very curious how many of those cardiologists will respond and augment therapy quickly to get the LDL cholesterol levels down, as compared with the study-directed treatment arm. And then of course, we really want to understand how effective is inclisiran in this particular immediate post-infarction event scenario?

Critically, we have not yet built the experience for those early months post-infarction when the risk is very high for a recurrent event, and the potential to further reduce that risk is present. Is the drug just as well tolerated in this setting? Is it just as effective at lowering LDL levels in those first few months as it was in the more chronic studies?”

Medicom: Do you have any safety concerns?

“No. I’ve been working in the ORION study program for over 4 years; my experience is consistent with that of the study as a whole. Namely, the number of side effects were identical to that in the placebo group. There wasn’t any signal except somewhat more injection site reactions in the active therapy group than the placebo group. So far, the effects of inclisiran are very encouraging in terms of its impact on liver function, impact on muscle function, renal function and so forth. Inclisiran has a highly encouraging safety profile.

Regarding adherence, once we give the shot, adherence is a 100% for the next 3 to 6 months, depending on when the next injection is due. We can keep track of adherence 100%, whereas if you’re dependent on taking a pill, we just don’t know if they’re taking it for example, or how frequently. I had just had a patient today that claimed to be on a statin, and we drew the levels and her LDL had gone quite up since last time we had seen her. Adherence has been an issue we all struggle with in the cardiologist clinic.”

Medicom: Do you have any final comments?

“We know that LDL cholesterol is now a causal factor for cardiovascular events; there are a lot of data. If an agent lowers LDL cholesterol with a very clean safety record, I think there is very strong evidence to suggest that it should also lower events. Obviously, we want to see the results of the outcomes trial, that’s necessary. However, in the shorter term, the data from VICTORION-INCEPTION will provide a strong impetus for early intervention with aggressive lipid-lowering treatments immediately post-infarction. We will see if inclisiran is well tolerated, safely lowers LDL cholesterol, and achieves the target range more frequently than with standard care alone. I think that that will be really an important observation.”


  1. Anderson J, et al. A Randomized Study to Compare LDL-C-Lowering Effects of Inclisiran With Usual Care vs Usual Care Alone in Patients With Recent Hospitalization for an Acute Coronary Syndrome: Rationale and Design of the VICTORION-INCEPTION Trial. Abstract 10851, AHA Scientific Sessions, November 5-7, 2022. https://www.ahajournals.org/doi/abs/10.1161/circ.146.suppl_1.10851
  2. Ray KK, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med. 2017 Apr 13;376(15):1430-1440.
  3. Raal FJ, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Apr 16;382(16):1520-1530.
  4. Ray KK, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519.
  5. Ray KK, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2022 Nov 4:ehac594
  6. Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr, Waring AA, Wilkins JT. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418.

Copyright ©2022 Medicom Medical Publishers

Posted on